Product Name: CD30 Antibody [CD30/412]
Species Reactivity: Human
Tested Applications: ELISA, Flow, IHC
Applications: ELISA: order BSA-free format for coatingFlow Cytometry: 0.5-1 ug/million cellsIF: 1-2 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 minutes at RT (1)Prediluted format : incubate for 30 min at RT (2)The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD30 antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Human CD30 recombinant protein was used as the immungen for this antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1604810-83-4
Product: THZ1
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Tumor necrosis factor receptor superfamily member 8, CD30L receptor, Ki-1 antigen, Lymphocyte activation antigen CD30, CD30, TNFRSF8, CD30, D1S166E
Accession NO.:
Protein Ino:
Official Symbol: TNFRSF8
Geneid: 943
Background: The antibody recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin’s disease, CD30 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This antibody distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the CD30 positive lymphomas lack the leukocyte common antigen (CD45).
PubMed ID:http://aac.asm.org/content/34/6/1210.abstract
